Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC Wainwright

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 287.10% from the stock’s current price.

A number of other brokerages have also commented on COYA. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. BTIG Research raised their price objective on Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, January 8th. Finally, Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Price Performance

COYA opened at $4.65 on Monday. The company has a market capitalization of $97.28 million, a price-to-earnings ratio of -4.19 and a beta of 0.27. The business’s 50-day moving average price is $5.41 and its two-hundred day moving average price is $5.89. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $8.29.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. Sell-side analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. bought a new position in Coya Therapeutics in the 4th quarter worth approximately $81,000. JPMorgan Chase & Co. purchased a new position in Coya Therapeutics during the third quarter worth about $28,000. Lantern Wealth Advisors LLC bought a new position in shares of Coya Therapeutics in the third quarter worth approximately $66,000. Prosperity Wealth Management Inc. grew its stake in Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in Coya Therapeutics by 51.3% in the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after acquiring an additional 22,120 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.